Skip to content

Study · Non-randomized trial · n = 10 · 1989

3 results

Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory.

Brambilla F, Bondiolotti GP, Maggioni M, Sciascia A, Grillo W, Sanna F, Latina A, Picotti GB

Neuropsychobiology1 Jan 1989Cited by 21 (Europe PMC)

PMID2548116 (opens in a new tab)DOI10.1159/000118483 (opens in a new tab)PepBankPUB-02548116
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In chronic undifferentiated schizophrenia, DDAVP significantly improved negative symptoms during continued neuroleptic therapy.

    In plain wordsIn chronic schizophrenia, DDAVP significantly improved negative symptoms during continued neuroleptic therapy.

    Peptide
    Desmopressin
    Outcome
    Direction not reportedNegative symptoms
    Study

    n = 10

    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    4 micrograms · intramuscular · 20 daysAs given in this study (human).

    Source sentences

    Summary
    DDAVP therapy induced a significant improvement of negative symptomatology and a trend toward improvement of short- to medium-term memory.
    2 context sentences
    Summary · context
    Ten chronic undifferentiated schizophrenics, 6 men and 4 women, aged 28-63, with 6- to 31-year histories of the disease were given DDAVP to observe the effects of this neuropeptide on the prevalent negative symptoms of their illness.
    Summary · context
    Patients were maintained on neuroleptic therapy and first given a 20-day course of placebo followed by 20 days of DDAVP i.m., 4 micrograms
  2. 02HumanNon-randomized trialEfficacy outcome

    In chronic undifferentiated schizophrenia, DDAVP showed a trend toward improved short- to medium-term memory.

    In plain wordsIn chronic schizophrenia, DDAVP showed a trend toward better short- to medium-term memory.

    Peptide
    Desmopressin
    Outcome
    Direction not reportedShort- to medium-term memory
    Study

    n = 10

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    4 micrograms · intramuscular · 20 daysAs given in this study (human).

    Source sentences

    Summary
    DDAVP therapy induced a significant improvement of negative symptomatology and a trend toward improvement of short- to medium-term memory.
    2 context sentences
    Summary · context
    Ten chronic undifferentiated schizophrenics, 6 men and 4 women, aged 28-63, with 6- to 31-year histories of the disease were given DDAVP to observe the effects of this neuropeptide on the prevalent negative symptoms of their illness.
    Summary · context
    Patients were maintained on neuroleptic therapy and first given a 20-day course of placebo followed by 20 days of DDAVP i.m., 4 micrograms
  3. 03HumanNon-randomized trialMechanism

    In chronic schizophrenia, homovanillic acid, MHPG, 5-HIAA, DOPAC, and growth hormone response to clonidine did not change during DDAVP therapy.

    In plain wordsIn chronic schizophrenia, four neurochemical concentrations and the growth hormone response to clonidine did not change during DDAVP therapy.

    Peptide
    Desmopressin
    Outcome
    No significant changeNeurochemical concentrations and growth hormone response
    Study

    n = 10

    Outcome group
    Neuroendocrine Markers · Endocrine and hormones
    Studied dose
    4 micrograms · intramuscular · 20 daysAs given in this study (human).

    Source sentences

    Summary
    No changes in homovanillic acid, MHPG, 5-HIAA and DOPAC, nor of growth hormone response to clonidine stimulation were observed.
    2 context sentences
    Summary · context
    Ten chronic undifferentiated schizophrenics, 6 men and 4 women, aged 28-63, with 6- to 31-year histories of the disease were given DDAVP to observe the effects of this neuropeptide on the prevalent negative symptoms of their illness.
    Summary · context
    Patients were maintained on neuroleptic therapy and first given a 20-day course of placebo followed by 20 days of DDAVP i.m., 4 micrograms

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.